What is the primary driver behind the significant increase in Pfizer's revenue for this period?

The substantial increase in revenue is primarily driven by the inclusion of the operations and sales of Wyeth, which Pfizer acquired in October 2009. This acquisition significantly expanded Pfizer's product portfolio and market reach.

Why did Pfizer's income from continuing operations decrease so sharply, despite higher revenues?

The sharp decrease in income from continuing operations is largely attributable to significant one-time and acquisition-related expenses. These include substantial asset impairment charges on intangible assets acquired from Wyeth, costs associated with integrating Wyeth, restructuring charges, and other significant charges such as a large asbestos litigation settlement. These items, while not impacting the core ongoing business, significantly reduced reported net income.

What are the main challenges Pfizer anticipates in the near future?

Pfizer anticipates significant challenges including the loss of market exclusivity for major products such as Lipitor and Effexor XR, which will likely lead to increased generic competition and reduced revenues. Additionally, the company is navigating the impacts of the U.S. Healthcare Legislation, which is expected to affect revenues through increased rebates and fees.

Can you explain the 'Adjusted Income' metric and why Pfizer reports it?

Adjusted Income is a non-GAAP financial measure that Pfizer's management uses to assess performance. It excludes items like purchase accounting adjustments, acquisition-related costs, discontinued operations, and certain significant items. Pfizer reports it to provide investors with an "alternative view of performance" that management believes better reflects the ongoing operational results of its core businesses, separate from the significant impacts of acquisitions and restructuring.

PFE 10-Q Filed Nov 12, 2010

Summary

Pfizer Inc.'s third quarter and first nine months of 2010 results were significantly impacted by the acquisition of Wyeth, which closed in October 2009. Revenues saw substantial year-over-year increases due to the inclusion of Wyeth's operations. However, income from continuing operations showed a sharp decline, primarily driven by significant charges including purchase accounting adjustments, asset impairments related to acquired intangibles, restructuring and acquisition-related costs, and a substantial charge for asbestos litigation. The company also experienced a higher effective tax rate in 2010 compared to 2009. Despite the reported net income decline, Pfizer highlighted "Adjusted Income" which excludes these significant items, showing growth. The company also detailed upcoming challenges, notably the loss of exclusivity for key drugs like Lipitor and Effexor XR, and the impact of the U.S. Healthcare Legislation. Looking ahead, Pfizer announced a definitive agreement to acquire King Pharmaceuticals and other strategic partnerships, demonstrating continued focus on business development.

Key Highlights

1Revenues increased significantly by 39% in Q3 2010 and 50% in the first nine months of 2010, largely due to the inclusion of Wyeth's operations acquired in October 2009.
2Income from continuing operations decreased substantially by 70% in Q3 2010 and 31% in the first nine months of 2010, driven by significant acquisition-related costs, purchase accounting adjustments, and asset impairments.
3The company recorded significant asset impairment charges of $1.5 billion in Q3 2010 and $1.6 billion in the nine months, primarily related to intangible assets acquired in the Wyeth acquisition.
4Restructuring charges and certain acquisition-related costs totaled $2.1 billion in Q3 2010 and $2.7 billion in the nine months, primarily related to the integration of Wyeth.
5Effective tax rates increased to 39.2% in Q3 2010 and 37.2% in the nine months, compared to 27.5% and 27.3% respectively in the prior year, due to various factors including higher expenses related to Wyeth and the expiration of tax credits.
6Pfizer announced a definitive agreement to acquire King Pharmaceuticals for $3.6 billion, signaling continued strategic business development activity.
7The company faces significant upcoming challenges including the loss of exclusivity for key products like Lipitor and Effexor XR, and the ongoing impact of the U.S. Healthcare Legislation.

PFIZER INC Quarterly Report for Q3 Ended Oct 3, 2010

Summary

Key Highlights

Frequently Asked Questions